SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates

Every plan includes:

✓Signal-Driven Leads Based on YOUR ICP

✓Slack + Chrome real-time alerts

✓No duplicates — only new events

INDUSTRY FIRST

Syntis Bio closes $33 million in Series A funding led by Cerberus Ventures to enhance oral therapies for obesity and rare diseases.

Jul 01, 2025•3 months ago

Amount Raised

$33 Million

Round Type

series a

BostonBiotechnology

Investors

Cerity Partners VenturesColorcon VenturesPortal InnovationsSafar PartnersW. R. Berkley CorporationBold Capital PartnersApollo LabsWoori Venture PartnersMansueto InvestmentsCerberus Ventures

Description

Syntis Bio, a clinical-stage biopharmaceutical company, has completed $33 million in Series A financing led by Cerberus Ventures. The funding will support the advancement of its SYNT™ platform, including the SYNT-101 obesity program. Additionally, Syntis secured up to $5 million in non-dilutive grants from the NIH. This capital will help in further developing innovative oral therapies.

Company Information

Company

Syntis Bio

Location

Boston, Massachusetts, United States

About

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours.

FundzWatch™ Score

Medium Activity

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech